Pixyl.Neuro

by Pixyl  · Based in France → — AI-Powered Insight for Improved Patient Care
Neurology Radiology
Website Demo Contact
Claim this tool
Is this the maker? Claim the company →

Subscription
Regulatory Status Disclosed

Overview

Pixyl.Neuro is an FDA-cleared AI-powered medical device designed to assist radiologists and neurologists in the early and accurate detection of brain anomalies and changes on MRI scans. It focuses on neuroinflammatory and neurodegenerative disorders, providing quantitative and qualitative insights that can enhance diagnostic confidence and improve patient management.

The technology leverages advanced artificial intelligence to analyze brain MR images, identifying subtle lesions and changes that might be challenging to detect with the naked eye. This capability is particularly valuable in conditions such as multiple sclerosis, Alzheimer’s disease, and other neurological disorders where early detection and monitoring of disease progression are crucial for effective treatment and patient outcomes.

Pixyl.Neuro integrates seamlessly into existing clinical workflows, providing automated analysis and reporting. It aims to standardize image interpretation, reduce inter-reader variability, and free up valuable physician time by automating tedious measurement tasks. The tool’s ability to track changes over time supports longitudinal monitoring, helping clinicians assess treatment efficacy and disease evolution more precisely.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated lesion detection and segmentation
  • Quantitative lesion burden analysis
  • Longitudinal change tracking
  • Standardized reporting
  • Integration with PACS systems
  • Support for neuroinflammatory disorders (e.g., MS)
  • Support for neurodegenerative disorders (e.g., Alzheimer's)
  • AI-powered image analysis

Use Cases

  • Early detection of brain lesions
  • Monitoring disease progression in MS and other neurodegenerative diseases
  • Assessing treatment efficacy
  • Reducing inter-reader variability in MRI interpretation
  • Streamlining radiology workflow
  • Enhancing diagnostic confidence

What Physicians Need to Know

Evidence Base (guidelines, literature scope)
Pixyl.Neuro leverages advanced AI technology for brain MRI analysis in neuroinflammatory and neurodegenerative disorders. It has received FDA 510(k) clearance and CE-mark class IIa certification under the new Medical Device Regulations in the European Union, demonstrating adherence to regulatory guidelines. The software's structured reports are based on MS diagnostic criteria. Pixyl's AI technology has been recognized for its ability to predict future clinical disability of multiple sclerosis patients from a single MRI sequence.
Clinical Validation Studies
Pixyl.Neuro has demonstrated enhanced detection rates up to 28%. It has been rigorously tested and validated for accuracy and reproducibility of measured brain region volumes and lesion volumes. Studies have shown that AI-assisted radiological assessments using Pixyl.Neuro.MS significantly improved lesion detection in MS patients, particularly those with high lesion loads, compared to conventional readings. In a retrospective study of 83 MS patients, AI-assisted analysis identified new lesions in 30.1% of patients, compared to 14.6% with conventional reporting (p < 0.001). The software was tested on datasets from healthy subjects, multiple sclerosis patients, Alzheimer's patients, microangiopathy patients, and white matter hyperintensities patients. A 2022 study published in Frontiers in Neurology assessed the performance of an automated atlas-based quantification procedure (AQP) against manual delineation in realistic TBI phantoms, supporting the feasibility of this approach. The Dice similarity coefficient and precision showed no statistical difference between AQP, rater consensus, and ground truth lesion delineations. The intra-class correlation coefficient between AQP and manual delineation was 0.70 in realistic phantoms and 0.92 in patients with TBI.
Differential Diagnosis Support
Pixyl.Neuro quantifies brain region volumes and compares them to normative data to identify abnormal atrophy earlier, aiding in differential diagnosis for neurodegenerative and neuroinflammatory disorders like MS, NMO, and Alzheimer's Disease. It segments the whole brain, gray/white matter, ventricles, hippocampi, cortical lobes, and other key regions, computing volumes and tracking changes over time. Pixyl.Neuro.BV provides percentiles compared to a healthy control population of the same age for each quantified brain structure, flagging abnormalities when values are out of the typical range. It also highlights asymmetries and specific patterns of atrophy with visual displays (glass-brain, spider plots, plots with normative values) to support differential diagnosis.
Clinical Workflow Integration
Pixyl.Neuro is designed for seamless integration into existing radiology workflows and systems. It uses minimal MRI protocols and provides results in a matter of minutes (analysis time < 5 min). The software offers zero-click longitudinal analysis with automatic retrieval and co-registration of prior scans for simplified review. It automatically generates patient reports (AutoReport) based on its findings, filling in indication, technique, and clinically relevant impressions, which saves time and ensures consistency. Results are returned directly to the hospital PACS as DICOM overlays and structured reports. Pixyl.Neuro can also integrate with AI-powered worklists to highlight AI results, findings, and automatically prioritize urgent patient cases.
Decision Audit Trail
The software outputs quantitative reports on tissue and structure volume, changes relative to prior visits, and graphs to visualize volume evolution with respect to normative values. For MS, it provides quantitative reports on lesion location, volume, and evolution, as well as annotated MRI images with lesions labeled according to their evolution. These structured reports and annotated images can serve as an audit trail for clinical decisions.
Physician Tip

Pixyl.Neuro can significantly enhance the efficiency and accuracy of brain MRI interpretation, particularly for neurodegenerative and neuroinflammatory disorders. Leverage its rapid analysis (<5 minutes) and automated longitudinal comparisons to quickly identify subtle changes and disease activity. Pay close attention to the quantitative reports and visual displays (e.g., glass-brain, spider plots) for objective measurements and comparison to normative data, which can be invaluable for differential diagnosis and monitoring treatment efficacy. While the AI provides robust support, always integrate its findings with your comprehensive clinical assessment and patient history. The automated reporting can streamline your workflow, allowing more time for complex case review and patient consultation.

Pixyl.Neuro is designed for seamless integration into existing PACS and AI platforms. It supports DICOM format for both input and output, allowing results to be displayed on DICOM workstations. The solution is available directly from Pixyl and through select distributors, and can be accessed through users' preferred platforms directly from their workstations. It is compatible with routine MRI protocols, specifically 3D T1 Gradient Echo for volumetric analysis and 3D T2-FLAIR for hyperintensity detection, quantification, and categorization. The system is HIPAA & GDPR compliant and certified for secure healthcare-data hosting (HDS compliant).

Details

Category Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI
Pricing Subscription — Based on number of analyses and number of installations.
DeploymentAvailable directly from Pixyl, or via OEM, PACS, and AI platforms.
API AvailableUnknown
Data ExportUnknown
Compliance
BAA Available Yes AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

FDA 510(k) clearance received on November 20, 2023 (Class II). Intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from MRI images. Volumetric measurements may be compared to reference percentile data.
GDPRUnknown AI-estimated
Integrations
EHR Not specified
Specialties Neurology, Radiology

Social Proof

Customers>50 (as of May 2026)
Notable
UC Davis School of Medicine

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Pixyl.Neuro

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

NeurologyLive
FDA Clears AI-Powered Brain MRI Software Pixyl.Neuro | NeurologyLive
Pixyl.Neuro, an AI-powered medical technology, received FDA 510(k) clearance for detecting anomalies and changes in brain MR images for neuroinflammatory and neurodegenerative disorders. The software aims to improve detection and accelerate MRI reading time, having been used in over 12 countries prior to approval.
2023-11
Multiple Sclerosis News Today
FDA clears AI tool for detecting disease activity on MRI scans
Pixyl.Neuro, an AI-driven software for analyzing MRI scans to detect and monitor multiple sclerosis (MS) disease activity, has received 510(k) clearance from the U.S. FDA for clinical use. The software is designed to provide rapid diagnostic support and is already in use in over a dozen countries.
2023-11
Imaging Technology News
Pixyl receives FDA clearance for AI-powered brain MRI software Pixyl.Neuro
Pixyl announced FDA 510(k) clearance for Pixyl.Neuro, an AI software for brain MRI analysis that has shown enhanced detection rates up to 28%. This software automatically analyzes brain MRI images for rapid detection, early diagnosis, and objective monitoring of neurological disorders.
2023-12
PR Newswire
Pixyl receives FDA clearance for AI-powered brain MRI software Pixyl.Neuro
Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro, its next-generation AI software for brain MRI analysis, which has demonstrated enhanced detection rates up to 28%. The software automatically analyzes brain MRI images to support rapid detection, early diagnosis, and objective monitoring of neurological disorders.
2023-11
Health Tech World
AI-powered brain MRI software receives FDA clearance - Health Tech World
French medtech company Pixyl has received FDA 510(k) clearance for its Pixyl.Neuro software, an AI-powered tool for brain MRI analysis that has demonstrated enhanced detection rates of up to 28%. The platform is now approved in the US, adding to the 12 other countries where it is already in use.
2023-11
GlobeNewswire
Blackford and Pixyl Partner to Aid Detection and Monitoring of Neurological Diseases
Blackford and Pixyl have announced a commercial partnership to integrate Pixyl.Neuro, an AI software for brain MRI analysis, into the Blackford Platform. This collaboration aims to provide healthcare professionals with advanced tools for diagnosing and monitoring neuroinflammatory and neurodegenerative diseases.
2024-03
Frontiers in Neurology (via PMC)
Evaluation of two AI techniques for the detection of new T2/FLAIR lesions in the follow-up of multiple sclerosis patients - PMC
This study compares Pixyl.Neuro.MSu00ae and Jazzu00ae software for T2/FLAIR lesion detection in MS patients, finding both significantly improved new lesion detection compared to conventional readings. Pixyl.Neuro.MSu00ae readings averaged 2 min 46 s, demonstrating efficiency in clinical practice.
2025-10
American Journal of Neuroradiology
Deep Learningu2013Accelerated 3D FLAIR Enables Reliable MS Lesion Detection
This study found that deep learning-reconstructed FLAIR sequences enable reliable detection of demyelinating lesions in MS patients with reduced scan time, without loss of diagnostic information. Automated analysis by Pixyl.Neuro.MS confirmed complete concordance in lesion detection between sequences.
2026-05

Videos

Product demos, reviews, and walkthroughs for Pixyl.Neuro.

View all on YouTube

Frequently Asked Questions

Pixyl.Neuro is an AI-powered medical device designed to assist in the early and accurate diagnosis and monitoring of neurological disorders, particularly multiple sclerosis, by analyzing brain MRI scans. It integrates into your workflow by providing quantitative reports and visualizations that can supplement your radiological readings, aiming to enhance diagnostic confidence and track disease progression more objectively.
Pixyl.Neuro is a CE-marked medical device and holds FDA 510(k) clearance, indicating its compliance with stringent regulatory standards for safety and performance. The platform is designed with robust data security measures and adheres to data privacy regulations like HIPAA and GDPR, ensuring patient data is protected through anonymization and secure handling protocols.
Alternatives to Pixyl.Neuro often include other AI-driven quantitative MRI analysis platforms or manual volumetric assessments performed by neuroradiologists. Pixyl.Neuro differentiates itself through its validated accuracy in lesion detection and quantification, its comprehensive reporting, and its focus on improving inter-reader variability and efficiency compared to manual methods.
The pricing model for Pixyl.Neuro typically involves a subscription-based service, which can vary depending on the volume of scans and the specific features required. Reimbursement by insurance or healthcare systems can vary by region and specific clinical indication; it's advisable to consult with Pixyl.Neuro representatives for detailed information regarding your specific practice and location.
While highly accurate, Pixyl.Neuro's limitations may include its performance with very rare or atypical neurological conditions not extensively represented in its training data, or in cases of significant motion artifact on MRI scans. Physicians should always integrate Pixyl.Neuro's output with their clinical judgment, patient history, and other diagnostic information, especially in ambiguous or complex cases.
Pixyl.Neuro primarily focuses on the detection, quantification, and tracking of white matter lesions, particularly in the context of demyelinating diseases like multiple sclerosis. While it provides valuable metrics for lesion characteristics, definitive differentiation between lesion etiologies often still requires comprehensive clinical correlation and expert radiological interpretation.
Pixyl.Neuro typically offers comprehensive training programs for clinicians and technical staff to ensure effective and compliant use of the platform. This often includes onboarding sessions, user manuals, and ongoing technical support to address any questions or issues that may arise during its integration into your practice.

Compare Pixyl.Neuro

VS
Butterfly iQ3 Ultrasound System vs Pixyl.Neuro
Clinical Decision Support & Reference Adjacent · 65/100
These two tools are adjacent but not direct competitors. Butterfly iQ3 is a handheld, whole-body ultrasound system for point-of-care diagnostics, offering broad imaging capabilities. Pixyl.Neuro, on the other…
VS
Brainomix 360 e-CTA vs Pixyl.Neuro
Clinical Decision Support & Reference Adjacent · 65/100
Brainomix 360 e-CTA focuses on acute stroke, specifically analyzing CT angiography scans for large vessel occlusions and collateral assessment. Pixyl.Neuro, on the other hand, is designed for detecting…
VS
BriefCase vs Pixyl.Neuro
Clinical Decision Support & Reference Adjacent · 65/100
BriefCase is an AI-powered communication and collaboration solution that streamlines the sharing of critical medical imaging findings across various specialties, focusing on triage and notification for urgent cases.…

Related Tools

Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
Starts free, then $29/month for individual plan (save 10% annually). other plans: enthusiast ($99/month), business ($349/month), enterprise (contact sales).
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.
KATE AI
Mednition
Clinical Decision Support & Reference
KATE AI is a nurse-built clinical decision support tool for emergency departments that analyzes incoming patients in real-time to flag high-risk cases that standard acuity scoring might miss. It has supported over 5,000,000 patient visits, helping emergency teams deliver safer, faster, and more informed care.
Fee-based, not publicly disclosed.
MCG Health
MCG Health
Clinical Decision Support & Reference
MCG Health provides industry-leading evidence-based guidance and technologies to optimize health outcomes, drive operational efficiency, and achieve cost savings. Their solutions are utilized by thousands of hospitals, a majority of U.S. health plans, and various government health programs.
Contact for pricing

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-06-19 | First Added: 2026-06-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.